RANI

Rani Therapeutics Holdings Inc

Add to Watchlist

Advanced Chart

1.935

-0.185(-8.726%)1D

Line

Candle

YTD

High

2.150

Open

2.100

VWAP

2.03

Vol

2.72M

Mkt Cap

257.60M

Low

1.920

Amount

5.52M

EV/EBITDA(TTM)

Total Shares

26.30M

262.88M

EV/OCF(TTM)

P/S(TTM)

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

-0.120

-33.33%

-0.110

-50%

-0.080

-70.37%

Estimates Revision

The market is revising Upward the revenue expectations for Rani Therapeutics Holdings, Inc. (RANI) for FY2025, with the revenue forecasts being adjusted by 1381.28% over the past three months. During the same period, the stock price has changed by 266.48%.

Revenue Estimates for FY2025

Revise Upward

+1381.28%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-9.26%

In Past 3 Month

Stock Price

Go Up

+266.48%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast RANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RANI is 10.00 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.935

Low

9.00

Averages

10.00

High

11.00

Current: 1.935

Low

9.00

Averages

10.00

High

11.00

H.C. Wainwright

Brandon Folkes

Buy

initiated

$11

2025-10-21

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$11

2025-10-21

initiated

Buy

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes the company has "three significant value drivers," its platform technology RaniPill, a recently announced collaboration agreement with Chugai Pharmaceutical for the development of a hemophilia product, and potentially an additional five drug targets, as well as RT-114, an oral GLP-1/GLP-2 dual agonist candidate. It expects data readouts on RT-114 to be the biggest driver of near-term value creation for Rani shares.

Maxim Group

Maxim

Buy

maintain

$5 -> $10

2025-10-20

Reason

Maxim Group

Maxim

Price Target

$5 -> $10

2025-10-20

maintain

Buy

Reason

Maxim raised the firm's price target on Rani Therapeutics to $10 from $5 and keeps a Buy rating on the shares after the company announced a licensing deal with Chugai Pharmaceutical for RaniPill technology and a concurrent private placement to raise $60M in proceeds. The Chugai deal offers both non-dilutive financing as well as "key validation" for RaniPill, the analyst tells investors.

Oppenheimer

Outperform

NULL

downgrade

$14 -> $4

2025-05-16

Reason

Oppenheimer

Price Target

$14 -> $4

2025-05-16

downgrade

Outperform

NULL

Reason

Oppenheimer lowered the firm's price target on Rani Therapeutics to $4 from $14 and keeps an Outperform rating on the shares following quarterly and business update. The firm anticipates a mid-2025 initiation of the Phase 1 study for RT-114, an oral RaniPill containing 200microL of ProGen's GLP-1/GLP-2 receptor agonist, PG-102. In March, Rani presented preclinical data demonstrating comparable bioavailability between RT-114 and subcutaneous PG-102 supporting its potential as an effective oral obesity treatment. Oppenheimer views Rani's expansion into obesity as a value-driver, differentiated by tolerability and flexible dosing. Given the company's financial position and advancing RT-114/obesity becoming its prime focus, the firm removes RT-111/psoriasis from its valuation.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

2025-04-03

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

2025-04-03

Reiterates

Strong Buy

Reason

Canaccord Genuity

Edward Nash

Strong Buy

Maintains

2025-02-26

Reason

Canaccord Genuity

Edward Nash

Price Target

2025-02-26

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2025-02-07

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2025-02-07

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Rani Therapeutics Holdings Inc (RANI.O) is -4.03, compared to its 5-year average forward P/E of -5.56. For a more detailed relative valuation and DCF analysis to assess Rani Therapeutics Holdings Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.56

Current PE

-4.03

Overvalued PE

-0.07

Undervalued PE

-11.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.15

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.02

Undervalued EV/EBITDA

-4.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

411.47

Current PS

2.12

Overvalued PS

1219.02

Undervalued PS

-396.08